Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Israel: These 24 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Israel: These 24 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Israel?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Israel Patent 199,077

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Israel?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Israel Patent 230,972

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Israel?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Israel Patent 198,806

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Israel?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Israel Patent 235,288
Patent Title: צורת מינון המכילה תרכובות המבוססות על 4–פניל–6–(2,2,2–טריפלואורו–1–פנילאתוקסי)פירימידין (Dosage form containing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds)

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can INLYTA (axitinib) generic drug versions launch in Israel?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Israel Patent 201,320

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Israel?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Israel Patent 201,256

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Israel?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Israel Patent 201,891

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Israel?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Israel Patent 238,840

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Israel?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Israel Patent 274,602

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Israel?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Israel Patent 201,571

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Israel?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Israel Patent 202,501

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Israel?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Israel Patent 202,501

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Israel?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Israel Patent 202,524

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Israel?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Israel Patent 280,401

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Israel?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Israel Patent 287,708

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch in Israel?

Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 18, 2027
Generic Entry Controlled by: Israel Patent 184,027
Patent Title: תרכובת טריסודיום [3-((1s, 3r)-1-ביפניל-4-ילמתיל-3-אתוקסיקרבוניל-1-בוטילקרבמויל)פרופיונאט-(s)-'3-מתיל-'2-(פנטהנויל{" 2-(טטרזול-5-ילאט)ביפניל-'4-ילמתיל}אמינו)בוטיראט] המיפנטההידראט, תכשירים רוקחיים שלה, שיטה להכנתה ושימוש בה להכנת תרופות (Compound trisodium [3-((1s,3r)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(s)-3’-methyl-2’-(pentanoyl{2’’-(tetrazol-5-ylate)biphenyl-4’-ylmethyl}amino)butyrate] hemipentahydrate, its pharmaceutical compositions, method for its preparation and use thereof in the preparation of medicaments)

Drug Price Trends for ENTRESTO SPRINKLE
ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. Additional details are available on the sacubitril; valsartan profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Israel?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Israel Patent 203,094
Patent Title: נגזרות פירימידיניל–פירידאזינון (Pyrimidinyl-pyridazinone derivatives)

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Israel?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Israel Patent 203,747
Patent Title: שימוש בפרקורסור של סטרויד מין בייצור תרופה למתן 13 מ" ג או פחות למינון יומי דרך הנרתיק לטיפול מחלות נרתיקיות ותכשיר רוקחי נרתיקי המכילה אותה (Use of sex steroid precursor in the manufacture of a medicament for delivering 13 mg or less daily dosage intrvaginally for the treatment of vaginal diseases and a vaginal pharmaceutical composition comprising same)

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can VIZAMYL (flutemetamol f-18) generic drug versions launch in Israel?

Generic name: flutemetamol f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 30, 2027
Generic Entry Controlled by: Israel Patent 203,316
Patent Title: תכשיר רוקחי רדיואקטיבי המכיל תרכובת בנזוטיאזול מסומנת ראדיואקטיבית ונשא כשיר ביולוגית ,שיטה להכנת התכשיר ושיטה לדימות על ידי שימוש בו (Radiopharmaceutical composition comprising isotopically-labeled benzothiazole compound and a biocompatible carrier, a method for preparing the composition and a method of imaging using the same)

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. Additional details are available on the flutemetamol f-18 profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Israel?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Israel Patent 204,500
Patent Title: תהליך לייצור הרכב או הרכב רוקחי על ידי ריסוס ציפוי של שכבת נתרן פיקוסולפאט על גרעין של אשלגן ביקרבונאט (Process for the manufacture of a composition or pharmaceutical composition comprising spray coating a layer of sodium picosulphate on a core of potassium bicarbonate)

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can XTANDI (enzalutamide) generic drug versions launch in Israel?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 12, 2027
Generic Entry Controlled by: Israel Patent 187,328
Patent Title: N-מתיל-2-פלואורו-{4-[3-(4-ציאנו-3-טריפלואורומתילפניל)-5,5-דימתיל-4-אוקסו-2-תיאוקסו-אימידאזולידינ-1-איל]}בנזאמיד, תכשירים רוקחים המכילים אותו ושימוש בו להכנת תרופות (N-methyl-2-fluoro-{4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]}benzamide, pharmaceutical compositions comprising the same and uses thereof in the manufacture of medicaments)

XTANDI is a drug marketed by Astellas. There are seven patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. Additional details are available on the enzalutamide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Israel?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Israel Patent 205,726
Patent Title: תכשירי רוקחות המיכילים אוקסי-הידרוקסיד של ברזל (Pharmaceutical compositions comprising iron oxy-hydroxide)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Israel?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Israel Patent 247,741
Patent Title: תכשירי רוקחות המכילים ברזל אוקסו - הידרוקסיד, שיטות להכנתם והשימושים בהם (Pharmaceutical compositions comprising iron oxy-hydroxide, methods for the preparation thereof and their uses)

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Israel?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Israel Patent 205,880
Patent Title: אנלוגי אמינוגליקוזידים, תכשירים המכילים אותם ושימושים בהם (Aminoglycoside analogs, compositions comprising the same and uses thereof)

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Israel?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Israel Patent 205,974

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Israel?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Israel Patent 211,429

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Israel?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Israel Patent 205,974

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Israel?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Israel Patent 211,429

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch in Israel?

Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Israel Patent 206,203

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty-three patents protecting this drug. There has been litigation on patents covering ORKAMBI

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. Additional details are available on the ivacaftor; lumacaftor profile page.

When can OLYSIO (simeprevir sodium) generic drug versions launch in Israel?

Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2027
Generic Entry Controlled by: Israel Patent 188,227
Patent Title: תרכובות מקרוציקליות, שילובים ותכשירים רוקחיים המכילים אותן, שימושים בהן כמעכבי וירוס הפטיטיס c ותהליכים להכנתן (Macrocyclic compounds, combinations and pharmaceutical compositions comprising them, uses thereof as inhibitors of hepatitis c virus and processes for their preparation)

OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug. There has been litigation on patents covering OLYSIO

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. Additional details are available on the simeprevir sodium profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Israel?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Israel Patent 206,448
Patent Title: משטר מינון הקשור לאסטרים פאליפרידונים להזרקה עם פעילות ממושכת (Dosing regimen associated with long acting injectable paliperidone esters)

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can RYTARY (carbidopa; levodopa) generic drug versions launch in Israel?

Generic name: carbidopa; levodopa
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 28, 2027
Generic Entry Controlled by: Israel Patent 248,520
Patent Title: תערובות שחרור מבוקרות של levodopa ושמושיהן (Controlled release formulation of levodopa and uses thereof)

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. Additional details are available on the carbidopa; levodopa profile page.

Israel Branded and Generic Drug Market Assessment: Regulation, Patent Risk, and Commercial Opportunities

Last updated: October 12, 2026

Israel is a small, high-income pharmaceutical market with centralized health coverage, strong clinical capabilities, and a large domestic generic manufacturer in Teva. Market access depends less on regulatory approval alone than on inclusion in the National Health Basket, negotiations with the four health funds, local distribution capability, and price competitiveness. Branded products retain opportunities in oncology, rare diseases, specialty care, and hospital medicines. Generic and biosimilar companies face aggressive pricing, procurement concentration, local registration requirements, and limited market scale.

What is the size and structure of Israel’s pharmaceutical market?

Israel’s pharmaceutical market is primarily financed through the National Health Insurance system, which covers residents through four health maintenance organizations: Clalit, Maccabi, Meuhedet, and Leumit. The Ministry of Health regulates medicines, while the National Health Basket determines which technologies receive public reimbursement.

Market characteristic Israel
Population Approximately 10 million
Primary regulator Israeli Ministry of Health, Pharmaceutical Division
Public reimbursement National Health Basket
Health funds Clalit, Maccabi, Meuhedet, Leumit
Core domestic manufacturer Teva Pharmaceutical Industries
Patent term Generally 20 years from filing
Supplementary protection Pharmaceutical patent term extension may apply
Regulatory model National registration, with reliance on recognized foreign approvals in some cases
Pricing environment Centrally negotiated and reference-price sensitive
EU membership No
U.S. FDA jurisdiction No, although FDA and EMA data are widely used

Israel’s medicines market is divided between community prescriptions, hospital procurement, over-the-counter products, and specialty medicines. Community dispensing is highly concentrated because the four health funds control most reimbursed outpatient utilization. Hospitals and health funds use tenders and framework purchasing to control expenditure.

The market is commercially attractive for products with high clinical value but difficult for undifferentiated products. Israel’s population limits absolute volume, while its clinical infrastructure supports early adoption, real-world evidence generation, and regional clinical development.

How does Israel’s branded drug market work?

Branded medicines obtain regulatory approval from the Ministry of Health but do not automatically receive public reimbursement. A manufacturer must generally pursue National Health Basket inclusion for broad public coverage.

The basket process creates a major commercial gate. Each year, manufacturers submit technologies for prioritization. A public committee evaluates clinical benefit, population impact, budget consequences, and health-policy considerations. The government then allocates a defined budget among competing technologies.

A product may therefore have three distinct commercial positions:

  1. Registered but not broadly reimbursed.
  2. Reimbursed for a restricted indication or patient subgroup.
  3. Included in the basket with broad access and health-fund purchasing.

The third position is usually required for major community-market revenue. Manufacturers often use evidence packages containing comparative efficacy, health-economic modeling, local epidemiology, budget impact, and international reimbursement precedent.

Which branded therapeutic areas have the strongest opportunities?

The strongest branded opportunities are concentrated in areas where clinical differentiation supports premium pricing:

  • Oncology and hematology.
  • Rare diseases and orphan medicines.
  • Immunology and inflammatory disease.
  • Neurology and advanced specialty care.
  • Cell and gene therapies.
  • Hospital anti-infectives and critical-care products.
  • Long-acting injectables and complex delivery systems.
  • Medicines that reduce hospitalization or invasive procedures.

Israel has a sophisticated hospital and research network, including large academic medical centers and extensive health-fund databases. These assets can support clinical trials, post-market studies, pharmacoeconomic evidence, and patient identification for precision therapies.

The principal commercial challenge is that a high list price does not translate directly into revenue. Health-fund restrictions, prior authorization, indication limits, tender pricing, and basket negotiations can materially reduce realized price.

What regulatory pathway applies to medicines in Israel?

The Israeli Ministry of Health’s Pharmaceutical Division is responsible for registration, manufacturing oversight, pharmacovigilance, imports, and related pharmaceutical controls. Applications generally rely on a complete quality, safety, and efficacy dossier, commonly in CTD format.

Israel accepts substantial international evidence, but approval by the U.S. FDA, European Medicines Agency, United Kingdom authorities, or other recognized regulators does not create automatic approval. The local authority can request additional information, local labeling, stability data, pharmacovigilance commitments, or clarification of manufacturing and supply arrangements.

What are the main regulatory requirements?

Manufacturers should plan for:

  • A local marketing authorization holder or authorized representative.
  • Hebrew labeling and patient information, with other language requirements depending on the product and channel.
  • Good Manufacturing Practice documentation.
  • Approved manufacturing and import sites.
  • Pharmacovigilance and adverse-event reporting.
  • Product registration and renewal obligations.
  • Controlled-substance or special-import permits where applicable.
  • Cold-chain validation for biologics and temperature-sensitive products.
  • Compliance with local packaging, serialization, and distribution rules.

Regulatory timelines vary by product type, dossier quality, application route, and the extent of Ministry questions. Products with recognized foreign approvals and complete documentation may move faster than novel products requiring extensive local review.

Israel’s regulatory system is not equivalent to the European centralized procedure. A European approval can materially support an Israeli filing, but it does not eliminate national requirements.

When do branded drugs lose exclusivity in Israel?

Patent protection generally lasts 20 years from the filing date under Israel’s Patent Law. Pharmaceutical products may qualify for a patent term extension, subject to statutory conditions and limitations. The extension is linked to regulatory approval timing and corresponding protection in recognized jurisdictions.

Regulatory exclusivity and patent protection should be analyzed separately. Israel does not operate a U.S.-style Orange Book system that publicly links every approved medicine, patent, and regulatory exclusivity period. The absence of a conventional Orange Book increases the importance of independent patent, registration, and litigation review.

Exclusivity issue Israel assessment
Basic patent term Generally 20 years from filing
Pharmaceutical term extension Available in qualifying cases, subject to statutory limits
Automatic patent linkage No U.S.-style automatic linkage regime
Public Orange Book No direct equivalent
Generic approval Based on regulatory and bioequivalence requirements
Biosimilar approval Requires a comparability-based dossier
Patent challenge Can arise through opposition, revocation, infringement, or market-entry disputes
Data protection Relevant protections exist, but scope and application differ from U.S. exclusivity rules

A company assessing generic launch timing must review composition-of-matter, formulation, polymorph, process, method-of-use, dosage, and device-related patents. A product can remain commercially protected after its primary compound patent expires if enforceable secondary patents cover the marketed presentation or indication.

How are generic drugs regulated and reimbursed in Israel?

Generic medicines are approved through abbreviated or reliance-supported pathways when the applicant can establish pharmaceutical equivalence, bioequivalence, quality, and manufacturing compliance. The Ministry of Health evaluates the reference product, dosage form, strength, route of administration, and evidence package.

Generic substitution and reimbursement are shaped by health-fund policies and procurement economics. Physicians may prescribe by brand or active ingredient, while pharmacists and health funds may influence substitution through reimbursement rules, preferred products, and patient copayments.

Generic companies face five principal barriers:

  1. Limited market volume relative to dossier, registration, and pharmacovigilance costs.
  2. Price erosion after multiple entrants.
  3. Tender-driven purchasing.
  4. Dependence on local distributors or health-fund access.
  5. Patent and regulatory disputes involving secondary protections.

Teva has major advantages in domestic manufacturing, regulatory experience, supply infrastructure, and physician recognition. International generic manufacturers can compete through complex generics, differentiated formulations, reliable supply, and products that address shortages or procurement gaps.

What biosimilar opportunities and risks exist in Israel?

Biosimilars have an opportunity in oncology, immunology, endocrinology, and supportive care. Public payers have an economic incentive to use lower-cost biologics, but adoption depends on physician confidence, interchangeability policy, prescribing controls, tender outcomes, and patient continuity.

The main risks are:

  • Unclear or evolving substitution practices for particular biologics.
  • Manufacturing complexity and high comparability costs.
  • Patent estates covering formulation, dosing, administration, and manufacturing.
  • Physician resistance where immunogenicity or switching concerns remain.
  • Small commercial volumes.
  • Procurement concentration among health funds and hospitals.

A biosimilar sponsor should treat the Ministry of Health dossier as only one part of market entry. Patent clearance, naming, pharmacovigilance, device compatibility, cold-chain reliability, and payer positioning can determine launch success.

What patent litigation and Paragraph IV challenges affect Israel?

Israel does not use the U.S. Hatch-Waxman Paragraph IV system in the same form. A generic company generally does not receive an automatic 30-month stay merely by challenging a listed patent because Israel has no equivalent Orange Book listing mechanism.

Patent disputes may involve:

  • Opposition or cancellation proceedings.
  • Revocation actions.
  • Infringement claims.
  • Declaratory relief.
  • Preliminary injunction applications.
  • Import and distribution disputes.
  • Patent term extension challenges.
  • Invalidity arguments based on lack of novelty, inventive step, enablement, or industrial applicability.

This structure can reduce the predictability of a U.S.-style launch timetable. A generic applicant must assess the patent estate independently and determine whether to launch at risk, seek a negotiated license, wait for expiry, or challenge relevant rights.

How strong is an Israeli pharmaceutical patent estate?

Patent strength depends on claim scope and enforceability rather than the number of patent families. A strong estate usually combines:

  • A valid compound patent or narrow product claim.
  • Enforceable formulation or dosage-form protection.
  • Claims covering commercially important indications.
  • Manufacturing claims that are difficult to design around.
  • A valid pharmaceutical term extension.
  • Consistent prosecution and ownership records.
  • Evidence supporting inventive step and enablement.

Weak estates often rely on late-filed, narrow method-of-use claims, routine formulation changes, or process claims that a generic manufacturer can avoid.

What formulation and method-of-use patents matter most?

Formulation patents can protect extended-release tablets, injectable depots, liposomal products, inhalation systems, transdermal delivery, stabilizers, excipients, particle size, crystal forms, and device configurations.

Method-of-use patents may cover:

  • A new indication.
  • A specific line of therapy.
  • Patient selection by biomarker.
  • Dosing intervals.
  • Combination treatment.
  • Reduced toxicity.
  • Treatment of a defined subgroup.

Their commercial value depends on whether the protected use is the principal reimbursed indication and whether prescribing controls can prevent widespread off-label substitution.

For generic entry, the practical question is whether the product can be approved and sold without practicing an enforceable claim. Label carve-outs, alternative dosing, different formulations, and non-infringing manufacturing routes may affect the analysis.

What commercial opportunities exist for foreign pharmaceutical companies?

Foreign companies can enter Israel through direct registration, a local marketing authorization holder, an Israeli distributor, licensing, co-promotion, or a local commercial subsidiary.

Licensing and partnership opportunities

Licensing is most attractive for:

  • Specialty products requiring health-fund access.
  • Orphan medicines with small patient populations.
  • Hospital products needing tender expertise.
  • Complex generics and biosimilars.
  • Products requiring local pharmacovigilance infrastructure.
  • Israeli-developed technologies seeking global commercialization.

Teva is the dominant local generic reference point, but Israel also has biotechnology, medical-device, diagnostics, and clinical-research companies that can support partnerships. A licensing agreement should allocate responsibility for registration, basket submissions, patent enforcement, supply continuity, recalls, pharmacovigilance, and tender participation.

What geographic coverage can Israel provide?

Israel is a national market, not an automatic gateway to the European Union. Israeli approval does not authorize sales in EU, U.S., or Gulf Cooperation Council markets. Its strategic value lies in:

  • Advanced clinical research.
  • Early-adopter physicians.
  • Strong electronic health-record infrastructure.
  • Regional scientific partnerships.
  • A technically capable healthcare workforce.
  • Potential evidence generation for international submissions.

Distribution relationships in Israel do not automatically provide access to neighboring markets, which may impose separate registration, import, pricing, and political requirements.

What are the main FDA and Israeli regulatory differences?

Issue United States Israel
Primary regulator FDA Israeli Ministry of Health
Generic pathway ANDA National abbreviated or reliance-supported pathway
Patent listing Orange Book No direct equivalent
Paragraph IV Formal statutory route No identical mechanism
Automatic stay Possible under Hatch-Waxman No equivalent automatic stay
Reimbursement Fragmented public and private payers National basket and health funds
Market access Payer-specific Basket and health-fund driven
Biosimilar framework BPCIA National comparability-based review
Price control Mixed Strong public-payer influence

A U.S. approval strategy can support Israeli registration, but U.S. patent conclusions do not transfer automatically. Israeli freedom-to-operate analysis must be conducted under Israeli law and based on the patents enforceable in Israel.

What generic launch scenarios exist in Israel?

A branded product facing loss of exclusivity generally has four launch scenarios:

Scenario Commercial result
Clean patent expiry with multiple entrants Rapid price erosion and tender competition
Secondary patent survives Delayed or restricted generic entry
Patent challenge succeeds Earlier entry with litigation cost
First entrant launches before full clearance Higher upside with injunction and damages risk

First-to-market economics are less powerful than in the United States because Israel’s population is smaller and health-fund procurement can quickly compress price. The best opportunities are often products with few registered competitors, supply shortages, complex dosage forms, or high clinical demand.

What are the key risks for investors and manufacturers?

The highest risks are regulatory delay, basket exclusion, tender price erosion, patent uncertainty, supply interruption, and dependence on a small number of buyers. Revenue forecasts should distinguish between total addressable patients, registered patients, basket-eligible patients, and patients actually treated.

Manufacturing and intellectual-property barriers are strongest for sterile injectables, biologics, inhaled products, modified-release systems, and products with complex device components. Local production can improve procurement credibility and supply resilience but requires capital, GMP compliance, technology transfer, and sustained utilization.

Key Takeaways

  • Israel is a regulated, reimbursement-concentrated market with high clinical sophistication and limited absolute volume.
  • Ministry of Health approval does not guarantee National Health Basket coverage.
  • The four health funds and hospital tenders materially influence realized price and market share.
  • Teva remains the principal domestic generic competitor and a major supply-chain reference.
  • Patent terms generally run 20 years from filing, with possible pharmaceutical term extension.
  • Israel has no direct U.S.-style Orange Book and no identical Paragraph IV mechanism.
  • Generic and biosimilar entry requires separate analysis of patent, regulatory, procurement, and substitution risks.
  • Branded opportunities are strongest in specialty, oncology, rare disease, advanced biologics, and clinically differentiated products.
  • Generic opportunities are strongest in complex products, supply-constrained categories, and markets with limited registered competition.
  • Israel is a standalone national market and does not provide automatic regulatory access to the EU, United States, or neighboring countries.

FAQs

Does Israel grant automatic approval to FDA-approved medicines?

No. FDA approval can support an Israeli application, but the Ministry of Health retains authority to assess the product, manufacturing sites, labeling, pharmacovigilance, and local requirements.

Is there an Israeli Orange Book for pharmaceutical patents?

No direct equivalent exists. Patent status must be assessed through Israeli patent records, regulatory information, ownership documents, and litigation history.

Can a generic launch before all Israeli patents expire?

Potentially, but the company must evaluate infringement, validity, patent term extension, injunction risk, and damages exposure under Israeli law.

Are biosimilars automatically interchangeable with reference biologics in Israel?

No automatic commercial assumption should be made. Substitution and switching depend on regulatory, clinical, payer, and health-fund practices applicable to the product.

Does National Health Basket inclusion guarantee market exclusivity?

No. Basket inclusion provides reimbursement access, not exclusivity. Competitors may receive approval and reimbursement, and health funds can use tenders, restrictions, and preferred-product policies.

References

  1. Israel Ministry of Health. (n.d.). Pharmaceutical Division: Registration and regulation of medicinal products. Government of Israel.

  2. Israel Ministry of Health. (n.d.). National Health Basket Committee and health technologies prioritization. Government of Israel.

  3. Israel Patent Office. (n.d.). Patent law and pharmaceutical patent term extensions. Government of Israel.

  4. OECD. (2023). Health at a glance 2023: OECD indicators. OECD Publishing.

  5. World Health Organization. (2023). Global benchmarking of medicines regulatory systems. World Health Organization.

  6. Teva Pharmaceutical Industries Ltd. (2023). Annual report 2023. Teva Pharmaceutical Industries Ltd.

  7. International Trade Administration. (2024). Israel country commercial guide: Healthcare and pharmaceuticals. U.S. Department of Commerce.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.